Friday 13 May 2022

US-based revenue cycle management solutions provider Med-Metrix, LLC, backed by A and M Capital Partners, has acquired patient engagement, front-end RCM software solutions provider PatientPal, Inc, the company said.

PatientPal is a provider of patient engagement, front-end RCM software solutions, including patient scheduling, price estimation, eligibility verification, prior authorization and payment solutions.

PatientPal's proprietary front-end RCM software further improves Med-Metrix's patient intake technology and service capabilities.

Financial terms of the transaction were not disclosed.

PatientPal will continue to serve over 40 customers in 35 states across a diversified mix of healthcare providers.

The acquisition augments Med-Metrix's Robotic Process Automation capabilities as PatientPal's software interacts with Electronic Medical Record systems, allowing for the automation of traditional front desk responsibilities.

PatientPal was founded in 2017 and is based in Boston, Massachusetts.

Under Med-Metrix, PatientPal will be rebranded within the Med-Metrix AnalytX suite of proprietary software products.

Med-Metrix is a technology-enabled services platform providing RCM and Business Intelligence solutions for health systems and physician groups across the United States.

Med-Metrix provides RCM and BI services via the company's proprietary software platform, AnalytX.

The company serves its customers through its Med-Metrix LLC, Medi-Centrix LLC, Physician Advisor On-Call, LLC, Miller and Milone, and ARMCO Partners divisions.

PatientPal automates and standardizes a contactless experience for practitioners and patients. From scheduling appointments all the way to final payment, PatientPal's front-end RCM technology solutions optimize all aspects of the patient experience.

PatientPal's solutions also include eligibility verification, price estimation, prior authorization, medical record access, surveys and reviews.

A and M Capital Partners is Alvarez and Marsal Capital's flagship investment strategy focused on middle-market control transactions in North America with total assets under management of approximately USD 2.7bn.